Allena Pharmaceuticals Announces $10.0 Million Registered Direct Offering of Common Stock
Allena intends to use the net proceeds to fund its clinical development programs and for working capital and other general corporate purposes, including the advancement of its lead candidate reloxaliase, an orally-administered, recombinant oxalate-degrading enzyme that is being developed for the treatment of enteric hyperoxaluria.
The securities described above are being offered pursuant to Allena’s shelf registration statement on Form S-3 (File No. 333-228656) filed with the
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This offering may only be made by means of a prospectus supplement and related base prospectus, forming a part of the effective registration statement.
About
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the timing and completion of the proposed offering and the expected use of proceeds from the proposed offering. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including those risks and uncertainties, and other important factors, set forth in the section entitled “Risk Factors” in Item 1A of Part II of Allena’s Quarterly Report on Form 10-Q for the quarter ended
Investor Contact
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
Media Contact
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com
Source: Allena Pharmaceuticals, Inc.